TOIIW (The Oncology Institute) Beneish M-Score: -2.88 (As of Jun. 26, 2026)


TOIIW The Oncology Institute Inc TOIIW
56 GF Score
Price $0.03
! 6 Warning Signs
View Full Analysis

What is The Oncology Institute Beneish M-Score?

The Oncology Institute TOIIW -47.27% 56 Beneish M-Score is -2.88 as of Jun. 26, 2026. GuruFocus rates TOIIW with a GF Score™ of 56/100. The stock has 6 warning signs investors should review. Among 633 Healthcare Providers & Services companies, The Oncology Institute ranks better than 73.46% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.88 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for The Oncology Institute's Beneish M-Score or its related term are showing as below:

TOIIW' s Beneish M-Score Range Over the Past 10 Years
Min: -3.89   Med: -3.1   Max: -1.03
Current: -2.88

During the past 8 years, the highest Beneish M-Score of The Oncology Institute was -1.03. The lowest was -3.89. And the median was -3.10.


The Oncology Institute Beneish M-Score Historical Data

* Premium members only.

The historical data trend for The Oncology Institute's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The Oncology Institute Beneish M-Score Chart

The Oncology Institute Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial -1.03 -2.27 -3.37 -3.35 -3.01

The Oncology Institute Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.88 -3.89 -3.25 -3.01 -2.88

TOIIW vs CCRN, SRTA, CYH: Beneish M-Score Comparison

For the Medical Care Facilities subindustry, The Oncology Institute's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


The Oncology Institute Beneish M-Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, The Oncology Institute's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where The Oncology Institute's Beneish M-Score falls into.


TOIIW
56GF Score
The Oncology Institute Inc TOIIW
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

The Oncology Institute Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of The Oncology Institute for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8842+0.528 * 0.9727+0.404 * 0.8095+0.892 * 1.3537+0.115 * 0.927
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.7645+4.679 * -0.109255-0.327 * 1.1118
=-2.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was $59.45 Mil.
Revenue was 147.441 + 141.957 + 136.564 + 119.802 = $545.76 Mil.
Gross Profit was 23.315 + 22.765 + 18.92 + 17.501 = $82.50 Mil.
Total Current Assets was $116.86 Mil.
Total Assets was $168.23 Mil.
Property, Plant and Equipment(Net PPE) was $33.22 Mil.
Depreciation, Depletion and Amortization(DDA) was $6.78 Mil.
Selling, General, & Admin. Expense(SGA) was $108.41 Mil.
Total Current Liabilities was $79.35 Mil.
Long-Term Debt & Capital Lease Obligation was $97.45 Mil.
Net Income was -2.492 + -7.508 + -16.504 + -17.009 = $-43.51 Mil.
Non Operating Income was 5.955 + 1.315 + -6.53 + -4.059 = $-3.32 Mil.
Cash Flow from Operations was -2.215 + 3.233 + -12.63 + -10.202 = $-21.81 Mil.
Total Receivables was $49.67 Mil.
Revenue was 104.406 + 100.267 + 99.901 + 98.578 = $403.15 Mil.
Gross Profit was 17.249 + 14.636 + 14.366 + 13.026 = $59.28 Mil.
Total Current Assets was $106.82 Mil.
Total Assets was $164.00 Mil.
Property, Plant and Equipment(Net PPE) was $35.33 Mil.
Depreciation, Depletion and Amortization(DDA) was $6.58 Mil.
Selling, General, & Admin. Expense(SGA) was $104.75 Mil.
Total Current Liabilities was $59.54 Mil.
Long-Term Debt & Capital Lease Obligation was $95.49 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(59.45 / 545.764) / (49.666 / 403.152)
=0.10893 / 0.123194
=0.8842

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(59.277 / 403.152) / (82.501 / 545.764)
=0.147034 / 0.151166
=0.9727

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (116.863 + 33.217) / 168.23) / (1 - (106.82 + 35.325) / 164.002)
=0.107888 / 0.133273
=0.8095

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=545.764 / 403.152
=1.3537

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(6.582 / (6.582 + 35.325)) / (6.776 / (6.776 + 33.217))
=0.157062 / 0.16943
=0.927

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(108.41 / 545.764) / (104.752 / 403.152)
=0.198639 / 0.259833
=0.7645

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((97.454 + 79.351) / 168.23) / ((95.49 + 59.541) / 164.002)
=1.050972 / 0.945299
=1.1118

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-43.513 - -3.319 - -21.814) / 168.23
=-0.109255

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The Oncology Institute has a M-score of -2.88 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.88 mean?
The Oncology Institute (TOIIW) has a Beneish M-Score of -2.88 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on The Oncology Institute and its competitors. According to the industry distribution chart, The Oncology Institute ranks #168 out of 633 companies in the Healthcare Providers & Services industry, placing it in the top 26.5%.
Is The Oncology Institute's Beneish M-Score too high?
The Oncology Institute's current Beneish M-Score is -2.88. Based on the distribution chart, The Oncology Institute ranks #168 out of 633 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, The Oncology Institute has a GF Score™ of 56/100, reflecting its overall financial health beyond just this single metric.
How does The Oncology Institute's Beneish M-Score compare to CCRN and SRTA?
According to the Healthcare Providers & Services industry distribution chart, The Oncology Institute ranks #168 out of 633 companies for Beneish M-Score. This puts The Oncology Institute in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Healthcare Providers & Services company?
A good Beneish M-Score depends on the Healthcare Providers & Services industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on The Oncology Institute and its competitors. The Oncology Institute's current Beneish M-Score is -2.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Oncology Institute stock overvalued right now?
The Oncology Institute (TOIIW) has a current Beneish M-Score of -2.88. The current Beneish M-Score is -2.88. The Oncology Institute's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For The Oncology Institute (TOIIW), the current Beneish M-Score is -2.88 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

The Oncology Institute Business Description

Other Exchanges TOI:USA
Address 18000 Studebaker Road, Suite 800, Cerritos, CA, USA, 90703
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
56GF Score

Get the complete analysis for TOIIW

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.03
Price